» Articles » PMID: 30304034

Hippo Signaling Pathway is Altered in Duchenne Muscular Dystrophy

Overview
Journal PLoS One
Date 2018 Oct 11
PMID 30304034
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Hippo signaling pathway is considered a key regulator of tissue homeostasis, cell proliferation, apoptosis and it is involved in cancer development. In skeletal muscle, YAP, a downstream target of the Hippo pathway, is an important player in myoblast proliferation, atrophy/hypertrophy regulation, and in mechano-trasduction, transferring mechanical signals into transcriptional responses. We studied components of Hippo pathway in muscle specimens from patients with Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, limb-girdle muscular dystrophy type 2A and type 2B and healthy subjects. Only DMD muscles had decreased YAP1 protein expression, increased LATS1/2 kinase activity, low Survivin mRNA expression and high miR-21 expression. In light of our novel results, a schematic model is postulated: low levels of YOD1 caused by increased inhibition by miR-21 lead to an increase of LATS1/2 activity which in turn augments phosphorylation of YAP. Reduced amount of active YAP, which is also a target of increased miR-21, causes decreased nuclear expression of YAP-mediated target genes. Since it is known that YAP has beneficial roles in promoting tissue repair and regeneration after injury so that its activation may be therapeutically useful, our results suggest that some components of Hippo pathway could become novel therapeutic targets for DMD treatment.

Citing Articles

Expression of Concern: Hippo signaling pathway is altered in Duchenne muscular dystrophy.

PLoS One. 2024; 19(6):e0306508.

PMID: 38935667 PMC: 11210769. DOI: 10.1371/journal.pone.0306508.


From adhesion complex to signaling hub: the dual role of dystroglycan.

Sciandra F, Bozzi M, Bigotti M Front Mol Biosci. 2023; 10:1325284.

PMID: 38155958 PMC: 10752950. DOI: 10.3389/fmolb.2023.1325284.


Dysregulated iron homeostasis in dystrophin-deficient cardiomyocytes: correction by gene editing and pharmacological treatment.

Andrysiak K, Machaj G, Priesmann D, Woznicka O, Martyniak A, Ylla G Cardiovasc Res. 2023; 120(1):69-81.

PMID: 38078368 PMC: 10898935. DOI: 10.1093/cvr/cvad182.


Sympatho-adrenergic mechanisms in heart failure: new insights into pathophysiology.

Du X Med Rev (2021). 2023; 1(1):47-77.

PMID: 37724075 PMC: 10388789. DOI: 10.1515/mr-2021-0007.


Decoding the transcriptome of Duchenne muscular dystrophy to the single nuclei level reveals clinical-genetic correlations.

Suarez-Calvet X, Fernandez-Simon E, Natera D, Jou C, Pinol-Jurado P, Villalobos E Cell Death Dis. 2023; 14(9):596.

PMID: 37673877 PMC: 10482944. DOI: 10.1038/s41419-023-06103-5.


References
1.
Ross S, Davis C . MicroRNA, nutrition, and cancer prevention. Adv Nutr. 2012; 2(6):472-85. PMC: 3226385. DOI: 10.3945/an.111.001206. View

2.
Altieri D . The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol. 2006; 18(6):609-15. DOI: 10.1016/j.ceb.2006.08.015. View

3.
Peltier H, Latham G . Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008; 14(5):844-52. PMC: 2327352. DOI: 10.1261/rna.939908. View

4.
Kim W, Jho E . The history and regulatory mechanism of the Hippo pathway. BMB Rep. 2018; 51(3):106-118. PMC: 5882217. DOI: 10.5483/bmbrep.2018.51.3.022. View

5.
Chakraborty S, Njah K, Pobbati A, Lim Y, Raju A, Lakshmanan M . Agrin as a Mechanotransduction Signal Regulating YAP through the Hippo Pathway. Cell Rep. 2017; 18(10):2464-2479. DOI: 10.1016/j.celrep.2017.02.041. View